German pharmaceutical company Merck KGaA (MRK.XE) said Tuesday it has appointed Stefan Oschmann as its new Chief Executive as of April 2016.
Mr. Oschmann will succeed Karl-Ludwig Kley, who has been CEO since April 2007 and is now retiring.
Born July 25, 1957 in Wuerzburg, Germany, Mr. Oschmann has served as member of the Merck executive board since 2011. He was initially in charge of its pharmaceutical business before being appointed deputy chairman of the executive board and deputy CEO at the start of 2015.
Before joining Merck, Mr. Oschmann worked at Merck & Co. of the U.S., which holds rights to the Merck designation but isn’t affiliated with the German Merck.
“We’re … happy to have found a successor in Stefan Oschmann early on, whose strategic foresight and strong leadership have turned Merck into a respected player in the pharma industry again,” said Johannes Baillou, chairman of the board of partners at E. Merck KG.
By Natascha Divac
Source: Wall Street Journal via MarketWatch
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
